Use of topical rapamycin as maintenance treatment after a single session of fractionated CO2 Laser Ablation: A method to enhance percutaneous drug delivery

Jongwook Oh, Jihee Kim, Won Jai Lee, Ju Hee Lee

Research output: Contribution to journalArticle

Abstract

Tuberous sclerosis complex (TSC) is an autosomal dominant neurocutaneous disorder with an incidence of approximately 1 in 5,000 to 10,000 live births. TSC has various clinical manifestations such as multiple hamartomas in systemic organs, including the skin. Angiofibromas are the most common skin lesions in patients with TSC. Although benign, angiofibromas develop in childhood and puberty, and can be psychosocially disfiguring for patients. Skin lesions in TSC, specifically angiofibromas, have no significant risk of malignant transformation after puberty; thus, they require no treatment if not prominent. However, the presentation of TSC is important owing to its impact on patient cosmesis. Surgical treatment and laser therapy are the mainstream treatments for angiofibromas. Although the evidence is limited, topical mammalian target of rapamycin inhibitors such as sirolimus (rapamycin) are effective in facial angiofibroma treatment. We describe an adult patient with an angiofibroma who had an excellent response to treatment with topical rapamycin after a single session of carbon dioxide (CO2) laser ablation. The patient showed no sign of relapse or recurring lesions for a year. CO2 laser ablation may serve as a new paradigm of treatment for angiofibromas in TSC. Since the selection of laser devices can be limited for some institutions, we suggest a rather basic but highly effective approach for angiofibroma treatment that can be generally applied with the classic CO2 device.

Original languageEnglish
Pages (from-to)555-558
Number of pages4
JournalAnnals of Dermatology
Volume31
Issue number5
DOIs
Publication statusPublished - 2019 Jan 1

Fingerprint

Angiofibroma
Gas Lasers
Laser Therapy
Sirolimus
Tuberous Sclerosis
Pharmaceutical Preparations
Therapeutics
Puberty
Skin
Neurocutaneous Syndromes
Equipment and Supplies
Hamartoma
Live Birth
Lasers
Recurrence

All Science Journal Classification (ASJC) codes

  • Dermatology

Cite this

@article{eb794c09548f4d73ab810ee91af292cd,
title = "Use of topical rapamycin as maintenance treatment after a single session of fractionated CO2 Laser Ablation: A method to enhance percutaneous drug delivery",
abstract = "Tuberous sclerosis complex (TSC) is an autosomal dominant neurocutaneous disorder with an incidence of approximately 1 in 5,000 to 10,000 live births. TSC has various clinical manifestations such as multiple hamartomas in systemic organs, including the skin. Angiofibromas are the most common skin lesions in patients with TSC. Although benign, angiofibromas develop in childhood and puberty, and can be psychosocially disfiguring for patients. Skin lesions in TSC, specifically angiofibromas, have no significant risk of malignant transformation after puberty; thus, they require no treatment if not prominent. However, the presentation of TSC is important owing to its impact on patient cosmesis. Surgical treatment and laser therapy are the mainstream treatments for angiofibromas. Although the evidence is limited, topical mammalian target of rapamycin inhibitors such as sirolimus (rapamycin) are effective in facial angiofibroma treatment. We describe an adult patient with an angiofibroma who had an excellent response to treatment with topical rapamycin after a single session of carbon dioxide (CO2) laser ablation. The patient showed no sign of relapse or recurring lesions for a year. CO2 laser ablation may serve as a new paradigm of treatment for angiofibromas in TSC. Since the selection of laser devices can be limited for some institutions, we suggest a rather basic but highly effective approach for angiofibroma treatment that can be generally applied with the classic CO2 device.",
author = "Jongwook Oh and Jihee Kim and Lee, {Won Jai} and Lee, {Ju Hee}",
year = "2019",
month = "1",
day = "1",
doi = "10.5021/ad.2019.31.5.555",
language = "English",
volume = "31",
pages = "555--558",
journal = "Annals of Dermatology",
issn = "1013-9087",
publisher = "Korean Dermatological Association",
number = "5",

}

Use of topical rapamycin as maintenance treatment after a single session of fractionated CO2 Laser Ablation : A method to enhance percutaneous drug delivery. / Oh, Jongwook; Kim, Jihee; Lee, Won Jai; Lee, Ju Hee.

In: Annals of Dermatology, Vol. 31, No. 5, 01.01.2019, p. 555-558.

Research output: Contribution to journalArticle

TY - JOUR

T1 - Use of topical rapamycin as maintenance treatment after a single session of fractionated CO2 Laser Ablation

T2 - A method to enhance percutaneous drug delivery

AU - Oh, Jongwook

AU - Kim, Jihee

AU - Lee, Won Jai

AU - Lee, Ju Hee

PY - 2019/1/1

Y1 - 2019/1/1

N2 - Tuberous sclerosis complex (TSC) is an autosomal dominant neurocutaneous disorder with an incidence of approximately 1 in 5,000 to 10,000 live births. TSC has various clinical manifestations such as multiple hamartomas in systemic organs, including the skin. Angiofibromas are the most common skin lesions in patients with TSC. Although benign, angiofibromas develop in childhood and puberty, and can be psychosocially disfiguring for patients. Skin lesions in TSC, specifically angiofibromas, have no significant risk of malignant transformation after puberty; thus, they require no treatment if not prominent. However, the presentation of TSC is important owing to its impact on patient cosmesis. Surgical treatment and laser therapy are the mainstream treatments for angiofibromas. Although the evidence is limited, topical mammalian target of rapamycin inhibitors such as sirolimus (rapamycin) are effective in facial angiofibroma treatment. We describe an adult patient with an angiofibroma who had an excellent response to treatment with topical rapamycin after a single session of carbon dioxide (CO2) laser ablation. The patient showed no sign of relapse or recurring lesions for a year. CO2 laser ablation may serve as a new paradigm of treatment for angiofibromas in TSC. Since the selection of laser devices can be limited for some institutions, we suggest a rather basic but highly effective approach for angiofibroma treatment that can be generally applied with the classic CO2 device.

AB - Tuberous sclerosis complex (TSC) is an autosomal dominant neurocutaneous disorder with an incidence of approximately 1 in 5,000 to 10,000 live births. TSC has various clinical manifestations such as multiple hamartomas in systemic organs, including the skin. Angiofibromas are the most common skin lesions in patients with TSC. Although benign, angiofibromas develop in childhood and puberty, and can be psychosocially disfiguring for patients. Skin lesions in TSC, specifically angiofibromas, have no significant risk of malignant transformation after puberty; thus, they require no treatment if not prominent. However, the presentation of TSC is important owing to its impact on patient cosmesis. Surgical treatment and laser therapy are the mainstream treatments for angiofibromas. Although the evidence is limited, topical mammalian target of rapamycin inhibitors such as sirolimus (rapamycin) are effective in facial angiofibroma treatment. We describe an adult patient with an angiofibroma who had an excellent response to treatment with topical rapamycin after a single session of carbon dioxide (CO2) laser ablation. The patient showed no sign of relapse or recurring lesions for a year. CO2 laser ablation may serve as a new paradigm of treatment for angiofibromas in TSC. Since the selection of laser devices can be limited for some institutions, we suggest a rather basic but highly effective approach for angiofibroma treatment that can be generally applied with the classic CO2 device.

UR - http://www.scopus.com/inward/record.url?scp=85072674518&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85072674518&partnerID=8YFLogxK

U2 - 10.5021/ad.2019.31.5.555

DO - 10.5021/ad.2019.31.5.555

M3 - Article

AN - SCOPUS:85072674518

VL - 31

SP - 555

EP - 558

JO - Annals of Dermatology

JF - Annals of Dermatology

SN - 1013-9087

IS - 5

ER -